JL1101EH - JL1101EH: Durability of Responses With Biweekly Dosing of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma Achieving a Clinical Response in the MajesTEC-1 Study

Presenter: Jessica Cheadle, NP

Authors

Saad Z Usmani¹, Lionel Karlin², Lotfi Benboubker³, Hareth Nahi⁴, Jesús San-Miguel⁵, Danielle Trancucci⁶, Keqin Qi⁷, Tara Stephenson⁸, Alfredo Perales Puchalt⁸, Katherine Chastain⁶, Ajai Chari⁹

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA; ² Centre Hospitalier Lyon Sud, France; ³ Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours, France; ⁴ Karolinska University Hospital at Huddinge, Stockholm, Sweden; ⁵ University of Navarra, Pamplona, Spain; ⁶Janssen Research & Development, Raritan, NJ, USA; ⁷ Janssen Research & Development, Titusville, NJ, USA; ⁸ Janssen Research & Development, Spring House, PA, USA; ⁹ Mount Sinai School of Medicine, New York, NY, USA